As of May 26
| -0.02 / -0.34%|
The 4 analysts offering 12-month price forecasts for Aratana Therapeutics Inc have a median target of 8.50, with a high estimate of 15.00 and a low estimate of 7.00. The median estimate represents a +44.07% increase from the last price of 5.90.
The current consensus among 5 polled investment analysts is to Buy stock in Aratana Therapeutics Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.